全文获取类型
收费全文 | 3282篇 |
免费 | 153篇 |
国内免费 | 11篇 |
学科分类
医药卫生 | 3446篇 |
出版年
2023年 | 21篇 |
2022年 | 20篇 |
2021年 | 107篇 |
2020年 | 75篇 |
2019年 | 86篇 |
2018年 | 107篇 |
2017年 | 83篇 |
2016年 | 122篇 |
2015年 | 96篇 |
2014年 | 180篇 |
2013年 | 176篇 |
2012年 | 277篇 |
2011年 | 297篇 |
2010年 | 143篇 |
2009年 | 126篇 |
2008年 | 219篇 |
2007年 | 184篇 |
2006年 | 163篇 |
2005年 | 147篇 |
2004年 | 134篇 |
2003年 | 112篇 |
2002年 | 84篇 |
2001年 | 52篇 |
2000年 | 38篇 |
1999年 | 29篇 |
1998年 | 18篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 9篇 |
1994年 | 10篇 |
1992年 | 24篇 |
1991年 | 21篇 |
1990年 | 12篇 |
1989年 | 23篇 |
1988年 | 22篇 |
1987年 | 18篇 |
1986年 | 13篇 |
1985年 | 16篇 |
1984年 | 23篇 |
1983年 | 9篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 14篇 |
1977年 | 15篇 |
1976年 | 7篇 |
1973年 | 9篇 |
1972年 | 14篇 |
1970年 | 6篇 |
1969年 | 10篇 |
1968年 | 6篇 |
排序方式: 共有3446条查询结果,搜索用时 203 毫秒
1.
Tarun Shankar Choudhary Akanksha Srivastava Ranadip Chowdhury Sunita Taneja Rajiv Bahl Jose Martines Maharaj Kishan Bhan Nita Bhandari 《Maternal & child nutrition》2019,15(4)
Burden and risk factors for wasting in the first 6 months of life among Indian children are not well documented. We used data from India's National Family Health Survey 4 to estimate the prevalence of severe wasting (weight for length < ‐3 SD) among 18,898 infants under 6 months of age. We also examined the association of severe wasting with household, maternal, and child‐related factors using multivariable logistic regression analysis. Prevalence of severe wasting among infants less than 6 months of age was 14.8%, ranging from 3.5 to 21% across states. Low birth weight (<2,500 g; adjusted odds ratio [AOR] 1.40, 95% CI [1.19, 1.65]), nonutilization of supplementary nutrition by mother during lactation (AOR 1.23, 95% CI [1.05, 1.43]), and anthropometric assessment during summer (AOR 1.37, 95% CI [1.13, 1.65]) and monsoon months (AOR 1.53, 95% CI [1.20, 1.95]) were associated with higher odds of severe wasting. Infants aged 2 to 3 months (AOR 0.78, 95% CI [0.66, 0.93]) and 4 to 5 months (AOR 0.65, 95% CI [0.55, 0.73]) had lower odds of severe wasting as compared with the 0‐ to 1‐month category. This analysis reveals a high burden of severe wasting in infants less than 6 months in India. Preventive interventions must be targeted at reducing low birth weight due to fatal growth restriction and prematurity. Appropriate care practices at facilities and postdischarge with extra attention to those born small and sick can prevent further deterioration in nutritional status. 相似文献
2.
Abhyuday Kumar Neeraj Kumar Dharani Lenin Amarjeet Kumar Shaheen Ahmad 《Indian Journal of Critical Care Medicine》2021,25(4):474
How to cite this article: Kumar A, Kumar N, Lenin D, Kumar A, Ahmad S. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19. Indian J Crit Care Med 2021;25(4):474–475.Sir,Itolizumab, an anti-CD6 humanized IgG1 monoclonal antibody, binds to domain-1 of CD-6 that is responsible for priming, activation, and differentiation of T-cells.[1] It significantly reduces T-cell proliferation along with substantial downregulation of the production of cytokines/chemokines.1 It was approved for moderate to severe chronic plaque psoriasis in 2013. However, it has recently been approved by the Drug Controller General of India for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.2 Here, we report a case of life-threatening infusion-related hypersensitivity reaction of itolizumab.A 65-year-old male COVID-19 patient got admitted to the intensive care unit (ICU) with complaints of shortness of breath and cough without any history of known disease. However, the baseline electrocardiogram (ECG) done in the ICU was suggestive of left bundle branch block (LBBB) (Fig. 1A). The patient was supported through noninvasive ventilation (NIV) and was started on remdesivir, dexamethasone, low-molecular-weight heparin, antibiotics, and other supportive treatment as per our institutional standard protocol. The patient was maintaining on continuous positive airway pressure mode of NIV with a fraction of inspired oxygen (FiO2) of 0.5 on the third day of ICU admission. Among the laboratory markers, the total leucocyte counts were raised (12,000/μL) with decreased lymphocytes (3.2%) and increased inflammatory markers (CRP, 320 mg/L; D dimer >20 μg/mL; LDH, 1694 U/L; IL6, 329 pg/mL). Serum electrolytes, renal function tests, liver function tests, and arterial blood gases were within acceptable limits. The patient was hemodynamically stable with a respiratory rate of 30 to 35/minute and a PO2/FiO2 ratio of 140. After taking informed written consent, inj. itolizumab was planned in this patient because of the increasing severity of the disease along with increased inflammatory markers. Inj. hydrocortisone 100 mg IV and inj. pheniramine 30 mg IV were given 30 minutes before itolizumab infusion. And 100 mg of itolizumab (Alzumab-L, Biocon Biologics) was diluted to 250 mL with normal saline and was started at 25 mL/hour. After about 20 minutes of infusion, the patient started complaining of shivering, sweating, and impending doom. The patient had sudden bronchospasm, and oxygen saturation dropped to 90%. ECG showed second-degree AV nodal block with an increased blood pressure of 180/110 mm Hg (Fig. 1B). The drug was immediately withdrawn and the patient was given a repeat dose of hydrocortisone and pheniramine along with other supportive measures. After sometime patients became alert and their respiratory symptoms were relieved. However, the second-degree heart block in ECG was persistent. ECHO was normal and troponin I was within normal limits while there was a slight increase in CPK-MB. The patient was observed closely and the ECG reverted to its previous state only after 24 hours. The patient was weaned from the ventilator in due course of time and put on face mask on the eighth day of stay.Open in a separate windowFigs 1A and B(A) Baseline ECG showing LBBB; (B) ECG showing second-degree AV nodal block after infusion reactionMost infusion reactions related to monoclonal antibodies are IgE mediated and are mild (grade 1 or 2) in nature.3 The incidence of severe (grade 3 or 4) reactions is generally low. The reported infusion-related reactions to itolizumab are chills/rigors (common), nausea, flushing, urticaria, cough, hypersensitivity, pruritus, rash, wheezing, dyspnea, oxygen desaturation, dizziness, headache, and hypertension. In our case, itolizumab infusion leads to a grade 4 reaction causing a persistent second-degree heart block for about 24 hours. Among the monoclonal antibodies, rituximab is most notorious for causing infusion reactions.4 There are only a few reports of cardiac arrhythmias (monomorphic VT, supraventricular tachycardia, trigeminy, and irregular pulse) during therapeutic infusion of rituximab,5 and there is no reported case of cardiac arrhythmia during itolizumab infusion. In our case, the patient was having LBBB and was on a QT prolonging drug (remdesivir), which might be a predisposing factor for the occurrence of second-degree heart block during infusion reaction. Premedications (e.g., antipyretics, antihistamines, and steroids) are recommended before the administration of some chemotherapeutic agents and monoclonal antibodies. These drugs should never be given as IV bolus and should always be given slowly in an infusion. Baseline assessments including vital signs and cognition should be documented carefully before the start of treatment and all the emergency equipment and drugs should be kept ready. Grade 3 and 4 reactions should be managed promptly with epinephrine, antihistaminics, and steroids along with other symptomatic supportive measures. As itolizumab is approved for emergency use in COVID-19, risk-benefit ratio should be assessed before prescribing this and should be explained before taking consent for infusion.The patient provided written informed consent for the publication. 相似文献
3.
Yong Tao Byunghak Kang Daniel A. Petkovich Yuba R. Bhandari Julie In Genevieve Stein-OBrien Xiangqian Kong Wenbing Xie Nicholas Zachos Shinji Maegawa Himani Vaidya Stephen Brown Ray-Whay Chiu Yen Xiaojian Shao Jai Thakor Zhihao Lu Yi Cai Yuezheng Zhang Hariharan Easwaran 《Cancer cell》2019,35(2):315-328.e6
4.
5.
6.
7.
8.
9.
Romila Chimoriya MD Neeraj Awasthy MD FNB Gaurav Kumar MD FNB Shubham Chelawat MD DNB 《Echocardiography (Mount Kisco, N.Y.)》2020,37(9):1470-1471
Tetralogy of Fallot is the most common cyanotic disease sharing a common anatomic basis but with varied presentation.There are very few described cases of TOF with left sided obstructive lesions. We describe a left ventricular outflow tract obstruction in a 3 year old child in association with TOF. Also we review the available literature for the association of left ventricular obstructive lesions in association with the same. 相似文献
10.